EMBER
09 Dec 2020
Trial Summary
A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ LocallyAdvanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Acronym:
EMBER
ACTRN/NCT /ethics:
NCT04188548
Scientific title:
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Sponsor / Cooperative group:
Eli Lilly and Company
Trial & Patient Characteristics
| Cancer Type | Breast |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Female |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2019-12-10 |
| Anticipated End Date | 2023-04-26 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Meena Okera |
| Recruitment Status | Recruiting |
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Meena Okera |
| Recruitment Status | Recruiting |